Results 31 to 40 of about 4,268 (199)

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women

Journal of the International AIDS Society, 2023
Introduction Multiple antiretroviral agents have demonstrated efficacy for human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP). As a result, clinical trials of novel agents have transitioned from placebo‐ to active‐controlled designs ...
Deborah Donnell, Fei Gao, James P. Hughes, Brett Hanscom, Lawrence Corey, Myron S. Cohen, Srilatha Edupuganti, Nyaradzo Mgodi, Helen Rees, Jared M. Baeten, Glenda Gray, Linda‐Gail Bekker, Mina Hosseinipour, Sinead Delany‐Moretlwe   +13 more
doaj   +1 more source

Long-Acting Cabotegravir for HIV/AIDS Prophylaxis

Biochemistry, 2021
The retrovirus HIV-1 is the etiological agent of the decades-long AIDS pandemic. Although vaccination is the most common preexposure route to prevent acquisition of viral disease, scalable efficacious vaccination strategies have yet to be developed for HIV-1.
Kathleen D. Engelman, Alan N. Engelman
openaire   +3 more sources

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women [PDF]

, 2021
Background: Safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection.
Landovitz, R.J., Rooney, J.F., Smith, K.Y., Hinojosa, J.C., Cohen, M.S., Frank, I., Anderson, P., Bryan, M., Sugarman, J., Spreen, W., Chariyalertsak, S., Marrazzo, J., Kelley, C.F., Lucas, J., Grinsztejn, B., Asmelash, A., Holtz, T.H., Eshleman, S.H., Scott, H., Santos, B., Huamani, J.V., Wang, Z., McCauley, M., Li, M., Donnell, D., Gallardo-Cartagena, J.A., Gulick, R.M., Phanuphak, N., Margolis, D., Madruga, J.V., Blanchette, C., Sista, N.D., Richardson, P., Rinehart, A., Tran, H.V., Adeyeye, A., Piwowar-Manning, E., Shin, K., Cabello, R., Gaur, A.H., Gomez-Feliciano, K., Brown, T.T., Jennings, A., Clement, M.E., Coelho, L., Losso, M.H., Del Rio, C., Marzinke, M., HPTN 083 Study Team, Hendrix, C., Daar, E., Eron, J.J., Kallas, E.G., Safren, S., Psaros, C., Fields, S.D., Gonzales, P., Sullivan, P., Cottle, L., Swaminathan, S., Overton, E.T., Sued, O., Hanscom, B., Dunne, E.F., Middelkoop, K., Kofron, R.M.   +65 more
core   +1 more source

Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir

Molecules, 2021
The long-acting parenteral formulation of the HIV integrase inhibitor cabotegravir (GSK744) is currently being developed to prevent HIV infections, benefiting from infrequent dosing and high efficacy.
Yanqiang Han, Hongyuan Luo, Qianqian Lu, Zeying Liu, Jinyun Liu, Jiarui Zhang, Zhiyun Wei, Jinjin Li   +7 more
doaj   +1 more source

Synthesis and biological evaluation of novel 1,2,3-triazole hybrids of cabotegravir: identification of potent antitumor activity against lung cancer

Frontiers in Pharmacology, 2023
In pursuit of discovering novel anticancer agents, we designed and synthesized a series of novel 1,2,3-triazole hybrids based on cabotegravir analogues.
Yajie Guo, Dan Sang, Bin Guo, Dan Wang, Dan Wang, Xinyue Xu, Xinyue Xu, Huili Wang, Cuilan Hou, Longfei Mao, Longfei Mao, Fang Li, Sanqiang Li   +12 more
doaj   +1 more source

Management of Drug-Drug Interactions between Long-Acting Cabotegravir and Rilpivirine and Comedications with Inducing Properties: A Modeling Study

, 2023
Background. Long-acting (LA) intramuscular cabotegravir and rilpivirine are prone to drug-drug interactions (DDI). However, given the long dosing interval, the conduct of clinical DDIs studies with LA antiretrovirals is challenging.
Marzolini, C., Marzolini, C, Bettonte, S., Battegay, M., Berton, M, Bettonte, S, Stader, F., Battegay, M, Stader, F, Berton, M.   +9 more
core   +1 more source

What will it take for an injectable ARV to change the face of the HIV epidemic in high‐prevalence countries? Considerations regarding drug costs and operations

Journal of the International AIDS Society, 2023
Introduction The proven effectiveness of injectable cabotegravir (CAB‐LA) is higher than that of any other HIV prevention intervention ever trialled or implemented, surpassing medical male circumcision, condoms and combination antiretroviral treatment ...
Gesine Meyer‐Rath, Lise Jamieson, Yogan Pillay   +2 more
doaj   +1 more source

Long‐acting cabotegravir and rilpivirine in people with HIV receiving chronic anticoagulation: A real‐world case series

British Journal of Clinical Pharmacology, EarlyView.
Background Long‐acting intramuscular cabotegravir plus rilpivirine (LA‐CAB + RPV) is an effective maintenance antiretroviral regimen for virologically suppressed people with HIV. However, its use in individuals receiving chronic anticoagulation is limited by concerns regarding intramuscular bleeding risk, and real‐world data are scarce.
Montserrat Laguno, Berta Torres, Maria Martínez‐Rebollar, Paula Arreba, Octavi Roman, Roger LLobet, Leire Berrocal, Alberto Foncillas, Júlia Calvo, Abiu Sempere, Ivan Chivite, Elisa de Lazzari, Josep Mallolas, Ana González‐Cordón   +13 more
wiley   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

British Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling, Lisanne A. H. Bevers, Wouter L. Smit, Rosa H. Elias, Annelies Verbon, David M. Burger, Berend J. van Welzen   +6 more
wiley   +1 more source

Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial

, 2019
Background: Cabotegravir (GSK1265744) is an integrase strand transfer inhibitor in development as a long-acting (LA) intramuscular injectable suspension for HIV-1 pre-exposure prophylaxis (PrEP).
Ian Frank (10438), Susan L. Ford (809764), David A. Margolis (563559), Miranda I. Murray (5984942), Kenneth H. Mayer (116219), Alex R. Rinehart (5945906), Britt S. Stancil (5984948), Martin Markowitz (67491), Robert M. Grant (128215), Parul Patel (5984951), William R. Spreen (5945909), Krischan J. Hudson (5984945)   +11 more
core   +1 more source